Seelos Therapeutics, Inc. announced an update to its Parkinson's Disease program SLS-007. Seelos is to begin an in-vivo study delivering SLS-007 by an Adeno-Associated Virus (AAV) vector making the program Seelos' second gene therapy approach for Parkinson's Disease (PD). Seelos is currently producing the viral vectors and preparing animals for this study. Data to determine delivery and target engagement is expected in the second half of this year. Seelos is also developing SLS-004, which is an all-in-one lentiviral vector gene therapy program that targets the SNCA gene that encodes for the production of a-synuclein.